Developing tests to detect and identify infectious bacteria
Task Area C: NIAID Preclinical Services for AMR Diagnostics Development
This study is working on better tests to quickly and accurately find harmful bacteria that can make people sick, helping doctors give the right treatment sooner, especially for infections that are hard to treat.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dynport Vaccine Company, LLC NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project ID | NIH-10913007 on NIH RePORTER |
What this research studies
This research focuses on creating and improving diagnostic tests that can accurately detect and identify various infectious bacteria affecting humans. By utilizing advanced biological assays, the project aims to enhance our understanding of bacterial drug resistance, which is a growing concern in healthcare. Patients may benefit from more effective diagnostic tools that can lead to timely and appropriate treatment options for bacterial infections. The research involves collaboration with various stakeholders to ensure that the developed assays meet clinical needs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing bacterial infections, particularly those with drug-resistant strains.
Not a fit: Patients with viral infections or those not affected by bacterial pathogens may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely diagnoses of bacterial infections, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown success in developing diagnostic assays for infectious agents, indicating that this approach has potential for impactful results.
Where this research is happening
Frederick, United States
- Dynport Vaccine Company, LLC — Frederick, United States (Active)
Researchers
- Principal investigator: Kallarkal, Abraham — Dynport Vaccine Company, LLC
- Study coordinator: Kallarkal, Abraham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.